Abstract
Objectives
To review whether levetiracetam is non-inferior to phenobarbitone as the first-choice antiseizure medication (ASM).
Methods
The authors searched Medline, Embase, Web of Science, Scopus, and Cochrane Library for randomized controlled trials (RCTs) published until May 31, 2023. RCTs comparing the efficacy and safety of levetiracetam and phenobarbitone as first-line ASM in neonatal seizures were included. Random effects meta-analysis was performed, and the Risk of Bias version 2 tool was used for quality assessment.
Results
Eleven RCTs enrolling 821 neonates [mostly term, with hypoxic-ischemic encephalopathy (HIE)] were included. There was no significant difference in seizure control between levetiracetam and phenobarbitone (10 RCTs, 786 participants; relative risk RR: 1.11; 95% CI: 0.79, 1.54; I2- 88%). Neonates in the levetiracetam group had a significantly lower incidence of hypotension (RR: 0.28; 95% CI: 0.09, 0.86), respiratory depression (RR: 0.36, 95% CI: 0.19, 0.66), and depressed sensorium (RR: 0.52, 95% CI: 0.27, 1.00). Three studies compared neurodevelopmental outcomes; however two of them were cross-over trials where infants received both drugs. Only one RCT enrolled pure cohorts and showed better neurodevelopment in the levetiracetam group at one month of age.
Conclusions
With the limitation of very-low certainty evidence, the results of this systematic review suggest that levetiracetam may be non-inferior to phenobarbitone for managing neonatal seizures. Considering a better safety profile and marginally better neurodevelopment in the short term, levetiracetam may be considered an initial choice for managing neonatal seizures.
Registration Number
PROSPERO (CRD42023438018).
Similar content being viewed by others
References
Yozawitz E. Neonatal seizures. N Engl J Med. 2023;388:1692–700.
Kharoshankaya L, Stevenson NJ, Livingstone V, et al. Seizure burden and neurodevelopmental outcome in neonates with hypoxic-ischemic encephalopathy. Dev Med Child Neurol. 2016;58:1242–8.
Verwoerd C, Limjoco J, Rajamanickam V, Knox A. Efficacy of levetiracetam and phenobarbital as first-line treatment for neonatal seizures. J Child Neurol. 2022;37:401–9.
Kumar J, Meena J, Yadav J, Saini L. Efficacy and safety of phenobarbitone as first-line treatment for neonatal seizure: A systematic review and meta-analysis. J Trop Pediatr. 2021;67:fmab008.
Gowda VK, Romana A, Shivanna NH, Benakappa N, Benakappa A. Levetiracetam versus phenobarbitone in neonatal seizures - a randomized controlled trial. Indian Pediatr. 2019;56:643–6.
Sharpe C, Reiner GE, Davis SL, et al. NEOLEV2 Investigators. Levetiracetam versus phenobarbital for neonatal seizures: A randomized controlled trial. Pediatrics. 2020;145:e20193182.
Xu Z-E, Li W-B, Qiao M-Y, et al. Comparative efficacy of anti-epileptic drugs for neonatal seizures: A network meta-analysis. Pediatr Neonatol. 2021;62:598–605.
Kaushal S, Tamer Z, Opoku F, Forcelli PA. Anticonvulsant drug-induced cell death in the developing white matter of the rodent brain. Epilepsia. 2016;57:727–34.
Falsaperla R, Mauceri L, Pavone P, et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: A single-center experience. Behav Neurol. 2019;2019:3683548.
Maitre NL, Smolinsky C, Slaughter JC, Stark AR. Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures. J Perinatol. 2013;33:841–6.
Komur M, Okuyaz C, Celik Y, et al. Neuroprotective effect of levetiracetam on hypoxic ischemic brain injury in neonatal rats. Childs Nerv Syst. 2014;30:1001–9.
Falsaperla R, Vitaliti G, Mauceri L, et al. Levetiracetam in neonatal seizures as first-line treatment: A prospective study. J Pediatr Neurosci. 2017;12:24–8.
Gyandeep G, Behura SS, Sahu SK, Panda SK. Comparison between phenobarbitone and levetiracetam as the initial anticonvulsant in preterm neonatal seizures - a pilot randomized control trial in developing country setup. Eur J Pediatr. 2023;182:2133–8.
Susnerwala S, Joshi A, Deshmukh L, Londhe A. Levetiracetam or phenobarbitone as a first-line anticonvulsant in asphyxiated term newborns? An open-label, single-center, randomized, controlled, pragmatic trial. Hosp Pediatr. 2022;12:647–53.
Pervez AFM, Badal MFA, Nabi SN, et al. Randomized controlled trial between levetiracetam and phenobarbital in the treatment of neonatal seizure due to perinatal asphyxia. Bangladesh J Child Health. 2018;42:67–72.
Perveen S, Singh A, Upadhyay A, Singh N, Chauhan R. A randomized controlled trial on comparison of phenobarbitone and levetiracetam for the treatment of neonatal seizures: Pilot study. Int J Res Med Sci. 2016;4:2073–8.
Prakash A, Richa R, Sahni GS. Neonatal seizures – levetiracetam versus phenobarbital. Indian J Child Health. 2019;6:605–8.
Akeel NE, Suliman HA, Al-Shokary AH, et al. A comparative study of levetiracetam and phenobarbital for neonatal seizures as a first line treatment. Glob Pediatr Health. 2022;9:2333794X221143572.
Shellhaas RA. Continuous long-term electroencephalography: The gold standard for neonatal seizure diagnosis. Semin Fetal Neonatal Med. 2015;20:149–53.
Hunt RW, Liley HG, Wagh D, et al. Effect of treatment of clinical seizures vs electrographic seizures in full-term and near-term neonates: A randomized clinical trial. JAMA Netw Open. 2021;4:e2139604.
Pressler RM, Cilio MR, Mizrahi EM, et al. The ILAE classification of seizures and the epilepsies: Modification for seizures in the neonate. Position paper by the ILAE Task Force on Neonatal Seizures. Epilepsia. 2021;62:615–28.
Sterne JAC, Savović J, Page MJ, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
Khan MTH, Rahman MM, Banerjee M, Uddin MZ, Nahar N, Akhter M. Comparative efficacy of phenobarbitone versus levetiracetam in the initial treatment of neonatal seizure. J Dhaka Med Coll. 2020;27:182–9.
Ghaffar J, Riaz A, Uzair Virk A, Bhatti A. Comparative efficacy of intravenous levetiracetam vs phenobarbitone in neonatal seizures. Medical Forum Monthly. 2020;31:25–8.
Pressler RM, Abend NS, Auvin S, et al. Treatment of seizures in the neonate: Guidelines and consensus-based recommendations-Special report from the ILAE Task Force on Neonatal Seizures. Epilepsia. 2023;64:2550–70.
Boylan GB, Rennie JM, Pressler RM, Wilson G, Morton M, Binnie CD. Phenobarbitone, neonatal seizures, and video-EEG. Arch Dis Child Fetal Neonatal Ed. 2002;86:F165–70.
Falsaperla R, Scalia B, Giugno A, et al. Treating the symptom or treating the disease in neonatal seizures: A systematic review of the literature. Ital J Pediatr. 2021;47:85.
Sharpe CM, Capparelli EV, Mower A, Farrell MJ, Soldin SJ, Haas RH. A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: Marked changes in pharmacokinetics occur during the first week of life. Pediatr Res. 2012;72:43–9.
Hnaini M, Darwich M, Koleilat N, et al. High-dose levetiracetam for neonatal seizures: A retrospective review. Seizure. 2020;82:7–11.
Favrais G, Ursino M, Mouchel C, et al. Levetiracetam optimal dose-finding as first-line treatment for neonatal seizures occurring in the context of hypoxic-ischaemic encephalopathy (LEVNEONAT-1): Study protocol of a phase II trial. BMJ Open. 2019;9:e022739.
Author information
Authors and Affiliations
Contributions
JK, BY: Conceived the idea, retrieved, and analyzed the data, and drafted the manuscript; JM, JY: Critical inputs in the protocol writing and data analysis and critically reviewed the manuscript; JKS: Critical inputs in the protocol, data analysis, interpretation of results, and revision of the initial draft. All authors approved the final version of the manuscript and are accountable for all aspects. JK and JKS will act as guarantors of the manuscript.
Corresponding author
Ethics declarations
Conflict of Interest
None.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
12098_2023_4905_MOESM5_ESM.docx
Supplementary Fig. S1 Risk of bias graph: A Review authors' judgment about each risk of bias item; B Risk of bias summary (DOCX 547 KB)
12098_2023_4905_MOESM6_ESM.docx
Supplementary Fig. S2 Forest plot showing a comparison of levetiracetam and phenobarbitone for adverse outcomes (DOCX 658 KB)
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Kumar, J., Yadav, B., Meena, J. et al. Levetiracetam versus Phenobarbitone for Management of Neonatal Seizures: A Systematic Review and Meta-analysis. Indian J Pediatr (2023). https://doi.org/10.1007/s12098-023-04905-1
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12098-023-04905-1